JP2023548855A5 - - Google Patents
Info
- Publication number
- JP2023548855A5 JP2023548855A5 JP2023526968A JP2023526968A JP2023548855A5 JP 2023548855 A5 JP2023548855 A5 JP 2023548855A5 JP 2023526968 A JP2023526968 A JP 2023526968A JP 2023526968 A JP2023526968 A JP 2023526968A JP 2023548855 A5 JP2023548855 A5 JP 2023548855A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- weight
- compound
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063110124P | 2020-11-05 | 2020-11-05 | |
| US63/110,124 | 2020-11-05 | ||
| PCT/US2021/057996 WO2022098828A1 (en) | 2020-11-05 | 2021-11-04 | Pharmaceutical compositions of a kinase inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026097956A Division JP2026134874A (ja) | 2020-11-05 | 2026-06-11 | キナーゼ阻害剤の医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023548855A JP2023548855A (ja) | 2023-11-21 |
| JP2023548855A5 true JP2023548855A5 (enExample) | 2024-11-12 |
| JP7879109B2 JP7879109B2 (ja) | 2026-06-23 |
Family
ID=78820880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023526968A Active JP7879109B2 (ja) | 2020-11-05 | 2021-11-04 | キナーゼ阻害剤の医薬組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230398108A1 (enExample) |
| EP (1) | EP4240333A1 (enExample) |
| JP (1) | JP7879109B2 (enExample) |
| KR (1) | KR20230104186A (enExample) |
| CN (1) | CN116406261A (enExample) |
| AU (1) | AU2021374669A1 (enExample) |
| CA (1) | CA3196001A1 (enExample) |
| CL (1) | CL2023001268A1 (enExample) |
| CO (1) | CO2023005942A2 (enExample) |
| CR (1) | CR20230223A (enExample) |
| GE (1) | GEAP202316262A (enExample) |
| IL (1) | IL302485A (enExample) |
| MX (1) | MX2023005273A (enExample) |
| PE (1) | PE20240223A1 (enExample) |
| WO (1) | WO2022098828A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20251184T1 (hr) * | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| AR127561A1 (es) * | 2021-11-03 | 2024-02-07 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de cinasas |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012009722A1 (en) * | 2010-07-16 | 2012-01-19 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
| ES2927651T3 (es) * | 2013-04-04 | 2022-11-10 | Exelixis Inc | Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer |
| WO2016079687A1 (en) * | 2014-11-18 | 2016-05-26 | Lupin Limited | Oral pharmaceutical composition of teriflunomide |
| HRP20251184T1 (hr) | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| PL3894012T4 (pl) | 2018-12-13 | 2026-01-05 | Exelixis, Inc. | Postacie krystaliczne i postacie soli inhibitora kinazy |
| CN116473973A (zh) * | 2018-12-24 | 2023-07-25 | 正大天晴药业集团股份有限公司 | 吡咯并嘧啶化合物的治疗用途及其固体药物组合物 |
-
2021
- 2021-11-04 IL IL302485A patent/IL302485A/en unknown
- 2021-11-04 WO PCT/US2021/057996 patent/WO2022098828A1/en not_active Ceased
- 2021-11-04 KR KR1020237017606A patent/KR20230104186A/ko active Pending
- 2021-11-04 EP EP21819284.7A patent/EP4240333A1/en active Pending
- 2021-11-04 CA CA3196001A patent/CA3196001A1/en active Pending
- 2021-11-04 PE PE2023001561A patent/PE20240223A1/es unknown
- 2021-11-04 CN CN202180074166.6A patent/CN116406261A/zh active Pending
- 2021-11-04 MX MX2023005273A patent/MX2023005273A/es unknown
- 2021-11-04 CR CR20230223A patent/CR20230223A/es unknown
- 2021-11-04 GE GEAP202316262A patent/GEAP202316262A/en unknown
- 2021-11-04 AU AU2021374669A patent/AU2021374669A1/en active Pending
- 2021-11-04 US US18/035,355 patent/US20230398108A1/en active Pending
- 2021-11-04 JP JP2023526968A patent/JP7879109B2/ja active Active
-
2023
- 2023-05-03 CL CL2023001268A patent/CL2023001268A1/es unknown
- 2023-05-09 CO CONC2023/0005942A patent/CO2023005942A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512117A5 (enExample) | ||
| CN106943355B (zh) | 药物组合物 | |
| JP5466179B2 (ja) | 生物学的利用能が改善されたエンタカポン、レボドパ及びカルビドパの医薬組成物 | |
| JP2022542804A5 (enExample) | ||
| US20070104785A1 (en) | Tablets of linezolid form iii and processes for their preparation | |
| JP2007503414A5 (enExample) | ||
| AU2019321583B2 (en) | Formulations of AG10 | |
| JP2023536667A5 (enExample) | ||
| CA2815280C (en) | A composition comprising s-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate and croscarmellose sodium | |
| US11576917B2 (en) | Pharmaceutical compositions comprising Ibrutinib | |
| WO2019203752A2 (en) | Combinations comprising a skeletal muscle relaxant agent and a multiple sclerosis treating agent | |
| US11730753B2 (en) | Stable pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride | |
| US20210267908A1 (en) | Pharmaceutical compositions of rivaroxaban | |
| JP5651478B2 (ja) | 糖アルコールと共微粒子化されたエンタカポンの医薬組成物 | |
| AU2013213255A1 (en) | Stable amorphous Raltegravir potassium premix and process for the preparation thereof | |
| WO2021091510A1 (en) | A capsule comprising eltrombopag olamine | |
| JP7233852B2 (ja) | 変色が抑制された固形製剤 | |
| WO2011081118A1 (ja) | 経口投与用医薬組成物 | |
| WO2017037645A1 (en) | Stable pharmaceutical formulations of teriflunomide | |
| JP2018184381A (ja) | エゼチミブ含有錠剤およびその製法 | |
| EP4199921A1 (en) | A solid oral composition comprising eltrombopag choline | |
| AU2007101090A4 (en) | Process for the preparation of a solid pharmaceutical dosage form | |
| JP7423297B2 (ja) | 口腔内崩壊錠およびその製造方法 | |
| EP2391350A1 (en) | Atazanavir formulations | |
| CA3187241A1 (en) | Pharmaceutical compositions comprising ribociclib |